Compare AbbVie Inc (ABBV) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Deckers Outdoor Corp — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while Deckers Outdoor Corp trades at $102.64 (market cap $14.73B). The key difference: AbbVie Inc is far larger — about 30.5× Deckers Outdoor Corp's market cap, and AbbVie Inc pays a 2.72% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals.
| ABBV | DECK | |
|---|---|---|
Market Cap | $449.91B | $14.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $123.91 |
52-Week Low | $184.85 | $79.54 |
Enterprise Value | $513.38B | $13.20B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Deckers Outdoor Corp (DECK) trades at $106.08, up 1.33% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.99B in 2025, with net income reaching $966M and a robust ROE of 40.86%. Recent quarters show consistent earnings beats, and analyst consensus targets $121.50. The stock benefits from international expansion of UGG and HOKA brands, as highlighted by Zacks Investment Research on 2026-07-01.
The outlook for DECK is positive, supported by earnings momentum and global growth initiatives, but risks include competitive pressures and market volatility. With a P/E of 15.05, the stock appears reasonably valued, offering potential upside to the consensus target. Investors should weigh strong profitability against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
